284 related articles for article (PubMed ID: 19630716)
1. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
Schaefer M; Mauss S
Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716
[TBL] [Abstract][Full Text] [Related]
2. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
[TBL] [Abstract][Full Text] [Related]
4. The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion.
Hong BA; North CS; Pollio DE; Abbacchi A; Debold C; Adewuyi SA; Lisker-Melman M
J Clin Psychol Med Settings; 2011 Mar; 18(1):99-107. PubMed ID: 21336614
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance.
Dimitroulopoulos D; Petroulaki E; Manolakopoulos S; Anagnostou O; Tsaklakidou D; Xinopoulos D; Tsamakidis K; Tzourmakliotis D; Paraskevas E
Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1407-12. PubMed ID: 19916203
[TBL] [Abstract][Full Text] [Related]
6. Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices.
Weiss JJ; Morgello S
Gen Hosp Psychiatry; 2009; 31(6):531-7. PubMed ID: 19892211
[TBL] [Abstract][Full Text] [Related]
7. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
Waizmann M; Ackermann G
J Subst Abuse Treat; 2010 Jun; 38(4):338-45. PubMed ID: 20362408
[TBL] [Abstract][Full Text] [Related]
8. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
Vignau J; Costisella O; Canva V; Imbenotte M; Duhamel A; Lhermitte M
Encephale; 2009 Oct; 35(5):477-83. PubMed ID: 19853722
[TBL] [Abstract][Full Text] [Related]
9. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
Schaefer M; Schwaiger M; Garkisch AS; Pich M; Hinzpeter A; Uebelhack R; Heinz A; van Boemmel F; Berg T
J Hepatol; 2005 Jun; 42(6):793-8. PubMed ID: 15885349
[TBL] [Abstract][Full Text] [Related]
10. [Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Montes ML; Fraile JM; González JJ; Arribas JR
Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):60-1. PubMed ID: 19218008
[No Abstract] [Full Text] [Related]
11. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
Sasadeusz JJ; Dore G; Kronborg I; Barton D; Yoshihara M; Weltman M
Addiction; 2011 May; 106(5):977-84. PubMed ID: 21205057
[TBL] [Abstract][Full Text] [Related]
12. Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.
Quarantini LC; Bressan RA; Galvão A; Batista-Neves S; Paraná R; Miranda-Scippa A
Liver Int; 2007 Oct; 27(8):1098-102. PubMed ID: 17845538
[TBL] [Abstract][Full Text] [Related]
13. Managing the neuropsychiatric complications of hepatitis C treatment.
Sockalingam S; Shammi C; Stergiopoulos V
Br J Hosp Med (Lond); 2007 Oct; 68(10):520-5. PubMed ID: 17974293
[TBL] [Abstract][Full Text] [Related]
14. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
Martín-Santos R; Díez-Quevedo C; Castellví P; Navinés R; Miquel M; Masnou H; Soler A; Ardevol M; García F; Galeras JA; Planas R; Solà R
Aliment Pharmacol Ther; 2008 Feb; 27(3):257-65. PubMed ID: 17988237
[TBL] [Abstract][Full Text] [Related]
15. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
Neri S; Bertino G; Petralia A; Giancarlo C; Rizzotto A; Calvagno GS; Mauceri B; Abate G; Boemi P; Di Pino A; Ignaccolo L; Vadalà G; Misseri M; Maiorca D; Mastrosimone G; Judica A; Palermo F
J Clin Gastroenterol; 2010 Oct; 44(9):e210-7. PubMed ID: 20838237
[TBL] [Abstract][Full Text] [Related]
16. Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.
Sockalingam S; Balderson K
Int Clin Psychopharmacol; 2005 Sep; 20(5):289-90. PubMed ID: 16096520
[TBL] [Abstract][Full Text] [Related]
17. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.
Schäfer A; Scheurlen M; Seufert J; Keicher C; Weissbrich B; Rieger P; Kraus MR
J Hepatol; 2010 Jan; 52(1):10-5. PubMed ID: 19897271
[TBL] [Abstract][Full Text] [Related]
18. [Hepatitis C, interferon a and depression: main physiopathologic hypothesis].
Vignau J; Karila L; Costisella O; Canva V
Encephale; 2005; 31(3):349-57. PubMed ID: 16142050
[TBL] [Abstract][Full Text] [Related]
19. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
Raison CL; Borisov AS; Broadwell SD; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
J Clin Psychiatry; 2005 Jan; 66(1):41-8. PubMed ID: 15669887
[TBL] [Abstract][Full Text] [Related]
20. [Alpha-interferon and mental disorders].
Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
